|Articles|August 1, 2003
Levofloxacin 1.5% concentration combats ocular pathogens
Fort Lauderdale, FL-Topical levofloxacin 1.5% (Santen), a new concentration of the drug in clinical development, achieves tear-fluid concentrations well above the reported minimum inhibitory concentrations (MIC) for the most common ocular pathogens, reported Tom R. Walters, MD, at the annual meeting of the Association for Research in Vision and Ophthalmology.
Advertisement
Newsletter
Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Ophthalmology Times - Clinical Insights for Eye Specialists
1
FDA grants IDE approval to EyeYon Medical for its US clinical study of EndoArt
2
Ocular Therapeutix accelerates NDA submission plans for AXPAXLI for wet AMD
3
First patient treated in ViaLase’s IDE trial
4
Formosa Pharmaceuticals and Rxilient sign licensing and commercialization agreement for APP13007
5











































.png)


